Evolving therapeutic options for type 2 diabetes mellitus: An overview

Postgraduate Medicine

Volumn 124, Issue 6, 2012, Pages 82-89

  Guthrie, Robert M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Dual peroxisome proliferator activated receptor modulator; G protein coupled receptor 119 agonist; G protein coupled receptor 40 agonist; Sodium glucose co transporter 2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ALOGLIPTIN; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; G PROTEIN COUPLED RECEPTOR AGONIST; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHENFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE CO TRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ARTICLE; DIABETES CONTROL; DIET THERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; KINESIOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; UNSPECIFIED SIDE EFFECT; REVIEW;

BIGUANIDES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

MLCS; MLOWN;

EID: 84875769415     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.11.2614     Document Type: Article

References (55)

1. Oral hypoglycaemic drugs. Br Med J. 1969;1(5647):829-831.
2. US Department of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research. Guidance for Industry: Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid-ances/ucm071627.pdf. December 2008. Accessed October 12, 2011.
3. National Institutes of Health. Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC). http://report.nih.gov/rcdc/ categories/. Accessed July 12, 2012.
4. American Diabetes Association. American Diabetes Association to Testify for Increased Diabetes Funding. http://www.diabetes.org/for-media/2010/american-diabetes-association-3.html. Accessed July 16, 2012.
5. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
6. Vaisrub S. Serendipitous sulphonylureas. JAMA. 1972;219(10):1335.
7. Stoner GD. Hyperosmolar hyperglycemic state. Am Fam Physician. 2005;71(9):1723-1730.
8. Pfeifer MA, Halter JB, Judzewitsch RG, et al. Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man. Diabetes Care. 1984;7(suppl 1):25-34.
9. Hadden DR. Goat's rue-French lilac-Italian fitch-Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edinb. 2005;35(3):258-260.
10. Rabinowitch IM. Observations on the use of synthalin in the treatment of diabetes mellitus. Can Med Assoc J. 1927;17(8):901-904.
11. Wise PH, Chapman M, Thomas DW, Clarkson AR, Harding PE, Edwards JB. Phenformin and lactic acidosis. Br Med J. 1976;1(6001): 70-72.
12. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 1998;352(9131):854-865.
13. Florez H, Luo J, Castillo-Florez S, et al. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med. 2010;122(2):112-120.
14. Fujii N, Jessen N, Goodyear LJ. AMP-activated protein kinase and the regulation of glucose transport. Am J Physiol Endocrinol Metab. 2006;291(5):E867-E877.
15. Gale EA. The discovery of type 1 diabetes. Diabetes. 2001;50(2): 217-226.
16. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11): 1106-1118.
17. GlaxoSmithKline's Avandia® (rosiglitazone maleate) reaches 20 million prescription milestone [news release]. Philadelphia, PA: PR News-wire; November 7, 2002. http://www.prnewswire.com/news-releases/ glaxosmithklines-avandiar-rosiglitazone-maleate-reaches-20-million-prescription-milestone-76702592.html. Accessed July 30, 2012.
18. Rogue A, Spire C, Brun M, Claude N, Guillouzo A. Gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR Res. 2010;2010:325183.
19. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003;108(23):2941-2948.
20. Nissen SE, Wolski K. Rosiglitazone revisited: an updated metaanalysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170(14):1191-1201.
21. Hurren KM, Taylor TN, Jaber LA. Antidiabetic prescribing trends and predictors of thiazolidinedione discontinuation following the 2007 rosiglitazone safety alert. Diabetes Res Clin Pract. 2011;93(1): 49-55.
22. Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation. 2010;121(16):1868-1877.
23. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-1188.
24. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916-922.
25. FDA drug safety communication: update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer [safety announcement]. Silver Spring, MD: US Food and Drug Administration; June 15, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm. Accessed July 30, 2012.
26. Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV Crit Rev Clin Lab Sci. 2003;40(3):209-294.
27. Lotfy M, Singh J, Kalasz H, Tekes K, Adeghate E. Medicinal chemistry and applications of incretins and DPP-4 inhibitors in the treatment of type 2 diabetes mellitus. Open Med Chem J. 2011;5(suppl 2):82-92.
28. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care. 2010;33(8):1859-1864.
29. Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev. 2011;27(4):362-372.
30. Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20(4):224-235.
31. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26 (7):540-549.
32. Deacon CF Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13(1):7-18.
33. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34(11):2474-2476.
34. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369.
35. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325(1):175-182.
36. Tradjenta® (linagliptin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2012; http:// bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/ Tradjenta/Tradjenta.pdf. Accessed July 30, 2012.
37. Onglyza® (saxagliptin) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011; http://packageinserts.bms.com/pi/pi_onglyza. pdf. Accessed July 29, 2012.
38. Januvia® (sitagliptin) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2012. http://www.merck.com/product/usa/pi_circulars/j/ januvia/januviapi.pdf. Accessed July 29, 2012.
39. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011;27(suppl 3):57-64.
40. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010; 95(1):34-42.
41. Hardman TC, Dubrey SW. Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther. 2011;2(3):133-145.
42. Araki T, Hirayama M, Hiroi S, Kaku K. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(3):271-278.
43. Kebede MA, Alquier T, Latour MG, Poitout V. Lipid receptors and islet function: therapeutic implications? Diabetes Obes Metab. 2009;11(suppl 4):10-20.
44. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J Pharmacol Exp Ther. 2012;340(2): 483-489.
45. Lin DC, Zhang J, Zhuang R, et al. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One. 2011;6(11):e27270.
46. Overton HA, Fyfe MC, Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol. 2008;153(suppl 1):S76-S81.
47. Lauffer L, Iakoubov R, Brubaker PL. GPR119: "double-dipping" for better glycemic control. Endocrinology. 2008;149(5):2035-2037.
48. Yoshida S, Tanaka H, Oshima H, et al. AS1907417, a novel GPR119 agonist, as an insulinotropic and beta-cell preservative agent for the treatment of type 2 diabetes. Biochem Biophys Res Commun. 2010;400(4):745-751.
49. Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9824):1403-1411.
50. Katz LB, Gambale JJ, Rothenberg PL, et al. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metab. 2012;14(8):709-716.
51. Ginsberg HN, Elam MB, Lovato LC, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.
52. Hansen BC, Tigno XT, Benardeau A, Meyer M, Sebokova E, Mizrahi J. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor cx/y agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome. Cardiovasc Diabetol. 2011;10:7.
53. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/ gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009;374(9684):126-135.
54. Su H, He M, Li H, et al. Boc5, a non-peptidic glucagon-like peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice. PLoS One. 2008;3(8):e2892.
55. Sando KR, Taylor J. Bromocriptine: its place in type 2 diabetes tx. J Fam Pract. 2011;60(11):E1-E5.